BioLineRx (BLRX) Asset Utilization Ratio (2024 - 2025)
BioLineRx (BLRX) recorded quarterly Asset Utilization Ratio of 0.03 in Q4 2025, down 90.46% quarter-over-quarter from 0.31 in Q3 2025, and down 95.37% on a YoY basis from 0.63 in Q4 2024.
BioLineRx (BLRX) Asset Utilization Ratio (2024 - 2025) Analysis & Trends
BioLineRx's Asset Utilization Ratio history runs 2 years deep, the most recent figure standing at 0.03 for Q4 2025.
- In Q4 2025, Asset Utilization Ratio fell 95.37% year-over-year to 0.03; the TTM figure through Dec 2025 stood at 0.03 (down 95.37% YoY), while the FY2025 annual figure was 0.03, down 94.75% from the prior year.
- Asset Utilization Ratio was 0.03 for Q4 2025 at BioLineRx, down from 0.31 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 0.63 in Q4 2024 to a low of 0.03 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 0.55 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.60 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 1,422.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | BioLineRx | 227.63 Mn | 211.90 Mn | 154,000.00 | 0.03 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.03 |
| Sep 30, 2025 | 0.31 |
| Jun 30, 2025 | 0.40 |
| Mar 31, 2025 | 0.54 |
| Dec 31, 2024 | 0.63 |
| Sep 30, 2024 | 0.29 |